• Education
  • Get the app
  • Country
    singapore
    hong kong
    malaysia
    indonesia
    thailand
    philippines
    vietnam
    india

    australia
    korea
    new zealand
The CIMS logo.
  • Home
  • Find Drugs
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The CIMS logo.
Home Find Drugs Find Drug Company Diseases Medical News & Updates
Other Services
CIMS Education Download App
Country
  • a globesingapore
  • a globehong kong
  • a globemalaysia
  • a globeindonesia
  • a globethailand
  • a globephilippines
  • a globevietnam
  • a globeaustralia
  • a globekorea
  • a globenew zealand
The CIMS logo.
  1. Home icon
  2. Medical News & Updates
    • Medical News & Updates
  3. List of News & Updates

News & Updates

Search

Showing Hepatology articles

Showing

MultidisciplinaryCardiologyDermatologyEndocrinologyGastroenterologyHepatologyInfectious DiseasesNeurologyObstetrics & GynaecologyOncologyOphthalmologyPaediatricsPsychiatryRespirologyRheumatologyUrologyPharmacy
MultidisciplinaryCardiologyDermatologyEndocrinologyGastroenterologyHepatologyInfectious DiseasesNeurologyObstetrics & GynaecologyOncologyOphthalmologyPaediatricsPsychiatryRespirologyRheumatologyUrologyPharmacy

Filters

Specialty:

MultidisciplinaryCardiologyDermatologyEndocrinologyGastroenterologyHepatologyInfectious DiseasesNeurologyObstetrics & GynaecologyOncologyOphthalmologyPaediatricsPsychiatryRespirologyRheumatologyUrologyPharmacy
Show Multimedia Only
Excessive sugary drink intake may lead to NAFLD

Excessive sugary drink intake may lead to NAFLD

12 Nov 2021

Drinking sugar-sweetened beverages (SSBs) at higher amounts contributes to an increase in liver fat in the long term, which in turn raises the likelihood of developing nonalcoholic fatty liver disease (NAFLD), especially among older people, according to a study.

12 Nov 2021
A3 adenosine receptor agonist safe, effective for treating NAFLD

A3 adenosine receptor agonist safe, effective for treating NAFLD

10 Nov 2021

Namodenoson, an A3 adenosine receptor (A3AR) agonist, shows clinical activity against nonalcoholic fatty liver disease (NAFLD) with or without nonalcoholic steatohepatitis (NASH), according to data from a phase II study.

10 Nov 2021
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 55
The CIMS logo.
  • Drugs
  • Find Drugs
  • Find Drug Company
  • CIMS Abbreviation Index
  • Diseases
  • Search Disease Information
  • Editorial Advisory Board
  • Medical News & Updates
  • Latest News & Updates
  • More Services
  • Education
  • Subscribe
  • About
  • MIMS Corporate
  • Terms of Use
  • Privacy Policy
  • Feedback
Connect with CIMS
A social media brand icon.A social media brand icon.A social media brand icon.A social media brand icon.A social media brand icon.
TUV Nord ISO 9001 certification logo
CIMS Specialty release/v3.16.0_3176.1
Copyright © 2026 CIMS Pte Ltd. All rights reserved. UAT
CIMS Logo

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?
Something went wrong.